Insys Therapeutics (NASDAQ: INSY) reported Q1 EPS of $0.63, $0.23 better than the analyst estimate of $0.40. Revenue for the quarter came in at $70.8 million versus the consensus estimate of $70.9 million.

Net income of $8.0 million, or $0.23 per basic and $0.21 per diluted share, compared to net income of $7.7 million, or $0.23 per basic and $0.21 per diluted share, for the first quarter of 2014.

The Company had $124.4 million in cash, restricted cash, cash equivalents, and short-term and long-term investments, no debt, and $184.6 million in stockholders' equity as of March 31, 2015.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.